Trabectedin Intermediate M24 CAS 308359-33-3 Purity ≥98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Trabectedin Intermediate M24 (CAS: 308359-33-3) with high quality. Please contact us by e-mail:alvin@ruifuchem.com
| Chemical Name | Trabectedin Intermediate M24 |
| Synonyms | (6R,6Ar,7R,13S,14R,16R)-5-(Acetyloxy)-6,6a,7,13,14,16-hexahydro-8-hydroxy-9-methoxy-4,10,23-trimethyl-19,20-dioxo-6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-14-carbonitrile); Trabectedin Intermediate A24 |
| Stock Status | In Stock |
| CAS Number | 308359-33-3 |
| Molecular Formula | C31H31N3O9S |
| Molecular Weight | 621.66 |
| COA & MSDS | Available |
| Origin of Product | Shanghai, China |
| Product Categories |
Trabectedin Intermediate |
| Brand | Ruifu Chemical |
| Items | Specifications |
| Appearance | White or Off-White to Yellowish Powder |
| Identification | Complies |
| Isomer | ≤0.10% |
| Related Substances | |
| Impurity A | ≤0.50% |
| Impurity B | ≤0.50% |
| Impurity C | ≤0.50% |
| Impurity D | ≤0.50% |
| Impurity E | ≤0.50% |
| Other Max. Impurity | ≤0.50% |
| Total Impurities | ≤2.0% |
| Purity | ≥98.0% (HPLC) |
Package:Bottle, 10g/100g/1kg/bag, or according to customer's requirement.
Storage Condition:Keep the container tightly closed. Store in a cool, dry and well-ventilated warehouse.
Shipping:Deliver to worldwide by air, by FedEx Express. Provide fast and reliable delivery.
Trabectedin Intermediate M24 (CAS: 308359-33-3) is mainly used for the synthesis of Trabectedin.
On October 23, 2015, FDA approved the listing of Trabetidinol (Trabectedin), a drug of Janssen (Janssen) Company, a subsidiary of Johnson & Johnson, under the trade name Yondelis. For the treatment of patients with non-resectable or metastatic liposarcoma and leiomyosarcoma who have received chemotherapy containing an anthracycline. Tribetete was designated as an alkylating agent as a cytotoxic drug. In 2007, EMEA approved it to be listed for the first time in Europe for the treatment of advanced soft tissue sarcoma. Later, it was approved to treat recurrent ovarian cancer in Europe and Canada. The manufacturers are Spanish biotechnology company Zeltia and Johnson and Johnson.
